Human Cystic Fibrosis iPSCs
Our Human Cystic Fibrosis iPSC line is derived from a 19-year-old male donor of Caucasian descent with a confirmed mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which plays a key role in mucus regulation. This genetic disorder primarily affects the lungs, pancreas, liver, kidneys, and intestines, leading to severe complications in respiratory and digestive functions.
Using our patented episomal reprogramming method, we have converted primary fibroblast cells into pluripotent stem cells without integrating viral or foreign DNA. Our proprietary transcription factor mix and small molecule chemistry provide a safe, consistent, and efficient reprogramming system, minimizing insertional mutagenesis risks while maintaining high fidelity for disease modeling and regenerative applications. We recommended culturing these cells in our Human iPSC Growth Media (CET-MR1001-K).
To enhance clinical safety, we omit c-Myc and Lin28 transcription factors, which are associated with neoplastic transformation. This ensures a lower clinical risk profile for downstream differentiation into lung epithelial cells and other tissue-specific models for cystic fibrosis research, drug screening, and gene therapy development.
Key Features & Quality Control:
- CFTR-mutant iPSC line validated for pluripotency
- Non-integrating, virus-free episomal reprogramming for genomic stability
- Confirmed mycoplasma-free and pathogen-free
- Cryopreserved at low passage for high viability upon thawing
Applications of Cystic Fibrosis iPSCs:
- Disease modeling for cystic fibrosis and airway dysfunction research
- Drug discovery and high-throughput screening of CFTR modulators
- Gene therapy development for personalized medicine for treatment of cystic fibrosis using iPSCs [i]
- Differentiation into lung epithelial cells, pancreatic cells, and other relevant tissues
Specifications:
- Donor Information: 19-year-old male, Caucasian descent with CFTR mutation
- Reprogramming Method: Non-integrating episomal DNA
- Mutation: CFTR gene mutation (variant details available upon request)
- Culture Conditions: Feeder-free, compatible with standard iPSC growth media
- Storage & Shipping: Cryopreserved, shipped on dry ice
Each vial contains ~500,000 cryopreserved cells, ensuring optimal viability and reproducibility for research applications
| Documents & Links for Human Cystic Fibrosis iPS Cells | |
| Datasheet | Human Cystic Fibrosis iPS Cells Datasheet |
| Vendor Page | Human Cystic Fibrosis iPS Cells at Cellular Engineering Technologies |
| Documents & Links for Human Cystic Fibrosis iPS Cells | |
| Datasheet | Human Cystic Fibrosis iPS Cells Datasheet |
| Vendor Page | Human Cystic Fibrosis iPS Cells |